Amphastar Pharmaceuticals (AMPH) Rating Increased to Strong-Buy at BidaskClub

Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

Other equities research analysts have also issued research reports about the stock. ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 17th. Needham & Company LLC reduced their price objective on shares of Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 10th. Finally, Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 10th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $21.00.

Amphastar Pharmaceuticals stock opened at $18.53 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94. Amphastar Pharmaceuticals has a 12 month low of $14.40 and a 12 month high of $20.45. The firm has a market cap of $872.86 million, a PE ratio of 49.82, a P/E/G ratio of 8.60 and a beta of 1.42.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, August 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.05). Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The company had revenue of $71.00 million for the quarter, compared to analysts’ expectations of $64.22 million. During the same quarter in the prior year, the firm earned $0.11 earnings per share. The company’s revenue was up 8.9% on a year-over-year basis. As a group, equities analysts expect that Amphastar Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 2,407 shares of the business’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $17.59, for a total transaction of $42,339.13. Following the completion of the transaction, the chief financial officer now owns 86,836 shares of the company’s stock, valued at approximately $1,527,445.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $17.82, for a total transaction of $178,200.00. The disclosure for this sale can be found here. 31.50% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Piedmont Investment Advisors LLC acquired a new position in Amphastar Pharmaceuticals during the 2nd quarter worth $128,000. Sei Investments Co. lifted its position in Amphastar Pharmaceuticals by 4.9% during the 2nd quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock worth $1,037,000 after acquiring an additional 3,193 shares during the last quarter. SG Americas Securities LLC acquired a new position in Amphastar Pharmaceuticals during the 2nd quarter worth $161,000. Principal Financial Group Inc. lifted its position in Amphastar Pharmaceuticals by 2.2% during the 1st quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after acquiring an additional 5,789 shares during the last quarter. Finally, BlackRock Inc. lifted its position in Amphastar Pharmaceuticals by 5.9% during the 2nd quarter. BlackRock Inc. now owns 5,720,183 shares of the company’s stock worth $87,291,000 after acquiring an additional 318,360 shares during the last quarter. 43.32% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Recommended Story: Float

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply